NCT00421278View on ClinicalTrials.gov

The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

January 31, 2007

Conditions
Atherosclerosis
Interventions
DRUG

MK0633

Single dose MK0633 100mg po in the fed state administered during a 4-wk study.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00421278 - The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED) | Biotech Hunter | Biotech Hunter